|
Taiwan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Taiwan Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Taiwan .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Taiwanese pharmaceutical and healthcare industry.
Competitive intelligence, Taiwanese pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Taiwanese market.
The Taiwan Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Taiwan Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Taiwanese pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Taiwan to test other views – a key input for successful budgeting and strategic business planning in the Taiwanese pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Taiwanese Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Taiwan .
- Exploit The Latest Competitive Taiwanese Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Taiwan .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Taiwan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Taiwan Pharmaceuticals And Healthcare Industry SWOT |
| Taiwan Political SWOT |
| Taiwan Economic SWOT |
| Taiwan Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q209 |
| Limits of Potential Returns |
| Risks to Realisation Of Returns |
Chapter - Taiwan – Market Summary |
| Regulatory Regime |
| Table: Examples Of Controlled Drugs In Taiwan |
| Table: Medicine Categories In Taiwan |
| Recent Regulatory Developments |
| Intellectual Property Regime |
| Intellectual Property Developments |
| Compulsory Licensing |
| Pricing Regime |
| Price Cuts |
| Reimbursement Regime |
| Table: Drug Reimbursement Principles |
| Recent Reimbursement Developments |
| Free Trade Agreements |
Chapter - Industry Trends and Developments |
| Epidemiology |
| Recent Public Health Developments |
| Healthcare System |
| Healthcare Financing |
| Table: Medical Care Institution Contracting And Management Of Taiwan's National Healthcare Insurance Fund (NHIF) For 2007 |
| Table: Statistics of Taiwan's National Healthcare Insurance Fund (NHIF) for 2007 |
| Table: Premium Contribution For Taiwan's Bureau Of National Health Insurance (% share) |
| Recent Healthcare System Developments |
| Domestic Pharmaceutical Sector |
| Foreign Company Activity |
| Traditional Chinese Medicine |
| Biotechnology Sector |
| Recent Biotechnology Developments |
| Medical Tourism |
| Vaccines |
| Recent Developments In The Vaccines Market |
| Medical Devices |
| Recent Developments In The Medical Devices Market |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Taiwan – Drug Expenditure Indicators, Historical Data And Forecasts |
| Key Growth Factors – Industry |
| Table: Taiwan – Health Expenditure Indicators, Historical Data And Forecasts |
| Key Growth Factors – Macroeconomic |
| Recession Unavoidable |
| Table: Taiwan - Economic Activity |
| Prescription Market Forecast |
| Table: Taiwan – Prescription Market Indicators, Historical Data And Forecasts (TWDmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Taiwan – Patented Drug Market Indicators, Historical Data And Forecasts |
| Generics Market Forecasts |
| Table: Taiwan – Generics Market Indicators, Historical Data And Forecasts |
| OTC Market Forecast |
| Table: Taiwan - OTC Market Indicators, Historical Data And Forecasts (TWDmn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table: Taiwan – Pharmaceutical Trade Indicators, Historical Data And Forecasts (US$mn) |
| Medical Device Market Forecast |
| Table: Taiwan – Medical Device Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Taiwan – Other Healthcare Indicators, Historical Data And Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Leading Pharmaceutical Companies By Revenue (US$mn) In Taiwan |
| Table: Taiwan's Pharmaceutical Market In Q406 |
Chapter - Company Profiles |
| Multinationals |
| Pfizer |
| Sanofi-Aventis |
| GlaxoSmithKline |
| Novartis |
| Merck & Co |
| Bayer Schering Pharma |
| Indigenous Manufacturers |
| Yung Shin Pharmaceutical (YSP) |
| ScinoPharm Taiwan |
| Synmosa Biopharma |
| Life Star Pharmaceutical |
| EMO Biomedicine Corporation |
| Empax Pharma |
| Purzer Pharmaceutical |
| Taiwan Biotech Co |
Chapter - Country Snapshot: Taiwan Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2000-2030 |
| Section 2: Labour Market And Spending Power |
| Table: Employment Indicators, 2000-2005 |
| Table: Consumer Expenditure, 2000-2005 (US$) |
| Table: Average Annual Manufacturing Wages, 2005-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Taiwan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Business Environment Rankings for Q209, Taiwan maintained its position of seventh out of the 15 key markets assessed in Asia Pacific, although its future placement is unlikely to improve significantly. Key drawbacks of the pharmaceutical market include the strict regulatory and pricing environment, which now includes the health technology assessment (HTA) system, despite its substantial (over 23mn) as well as rapidly ageing population. In fact, statistics released in March 2009 by the Ministry of the Interior (MOI) show that the number of the elderly accounted for 10.4% of the total population in 2008, while the ageing index increased from 40.9 in 2004 to 61.5 at the end of 2008. While the numbers illustrate a considerable potential for the commercialisation of various chronic and long-term treatments, the stringent reimbursement system and the emphasis on the usage of generics will continue to place downward pressure on the overall pharmaceutical values.
In the light of the above, the Taiwanese pharmaceutical market at consumer prices is expected to post a very modest compound annual growth rate (CAGR) of 3.99% in local currency terms. From an estimated US$4.55bn in 2008, the market valuation is forecast to reach US$5.47bn in 2013, which compares to over US$15bn for South Korea, for example, and its population of around 49mn. Among other factors acting as a brake on the faster development of the market is the lack of sound private financing, In the meantime, the new health insurance project '1.5 generation health insurance', launched on February 16 2009 despite widespread opposition, lasted only two days due to the fallout from the financial crisis.
Nevertheless, given that healthcare and medicines as seen as essential commodities, healthcare providers emerged as the key beneficiaries of Taiwan's bold US$2.5bn voucher scheme that was rolled out in early 2009. Coupons have reportedly been used for pharmaceuticals and other medical treatments across a number of healthcare facilities, although questions over the success and viability of the wider voucher scheme have been raised by many. Needless to say, the spending splurge (as well as lost tax revenue due to cuts and refunds) will come at a cost, in terms of a widened deficit, which we expect to rise to a still manageable 3.0% of GDP in 2009. In the meantime, Taiwan is facing a strong likelihood of the economy contracting in 2009. BMI's Country Risk team is forecasting a 6.5% decrease in GDP, which is one the most extreme contractions for a developed state.
On a positive note for the industry, in January 2009, US biotechnology company Amarillo Biosciences reported that its application to conduct a Phase II study of its low-dose hepatitis C drug in Taiwan was approved by the Department of Health. Around the same time, TaiGen Biotechnology, one of the leading Taiwanese development-stage pharmaceutical companies, successfully raised US$37mn from its existing shareholders and new investors through the private placement of stock. The additional capital will help TaiGen expand its product line – with a focus on oncology, chronic inflammation and viral infection – and expedite its growth.
|
Taiwan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |